4
ESSM
Today
Interview with Prof. Giuliano
investigation including Rho kinase inhibitors,
guanylate cyclase activators, compounds traget-
ting the bladder afferences.
JIMS: Prof. GIULIANO, regarding the latest
controversy about Testosterone Replacement
Therapy & Cardiovascular Risk, what is your
personal opinion about that?
I believe that testosterone replacement should
be used appropriately and with caution. This
story reminds me about the Women health initia-
tive (WHI) that led in the US to a significant de-
crease in the use of hormonal supplementation
in post menopausal women. It was reported that
most of men receiving testosterone in the US do
not have clinically meaningful low testosterone.
JIMS: And last but not least, which do you
consider the most important challenges for
our specialty (Sexual Medicine) and for our
society (ESSM) in the next 5 years?
The level of knowledge regarding the physiology
of male sexual response including the neuro-
physiology and pharmacology of ejaculation, the
physiology of orgasm is still limited. We must
remember that this is after and in parallel having
achieved significant progress in the physiology
of penile erection that effective treatments for
ED have been developed. Apart from premature
ejaculation, ejaculatory disorders and orgas-
mic problems remain unmet medical needs.
ESSM has tremendously supported the develop-
ment of good medical practices during the last
20 years. Ultimately European patients have
benefit of better care from well trained sexual
medicine physicians thanks to ESSM. The main
challenges for the next 5 years, but I am afraid
it will last longer, is in my opinion to design a
disease modifying treatment for ED instead of
symptomatic treatments and to increase the
knowledge regarding ejaculatory disorders. This
can achieved by engaging more scientists within
sexual medicine.
It was a great pleasure to interview you;
I am convinced that your points of view, fruits
of a lifetime devoted to your work, will be
highly appreciated by our readers. Thanks
once again.
Visit our website
